PL375113A1 - Casein derived peptides and uses thereof in therapy - Google Patents

Casein derived peptides and uses thereof in therapy

Info

Publication number
PL375113A1
PL375113A1 PL02375113A PL37511302A PL375113A1 PL 375113 A1 PL375113 A1 PL 375113A1 PL 02375113 A PL02375113 A PL 02375113A PL 37511302 A PL37511302 A PL 37511302A PL 375113 A1 PL375113 A1 PL 375113A1
Authority
PL
Poland
Prior art keywords
peptides
therapy
casein
derived peptides
derived
Prior art date
Application number
PL02375113A
Other languages
Polish (pl)
Inventor
Zvi Sidelman
Original Assignee
Chay 13 Medical Research Group N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/942,121 external-priority patent/US20020147144A1/en
Application filed by Chay 13 Medical Research Group N.V. filed Critical Chay 13 Medical Research Group N.V.
Publication of PL375113A1 publication Critical patent/PL375113A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4732—Casein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Biologically active peptides that are derived from or are similar to sequences identical with the N-terminus of the S1 fraction of milk casein. These peptides are capable of stimulating and enhancing immune response, protecting against viral infection, normalizing serum cholesterol levels, and stimulating hematopoiesis. The casein-derived peptides are non-toxic and can be used to treat and prevent immune pathologies, hypercholesterolemia, hematological disorders and viral-related diseases.
PL02375113A 2001-08-30 2002-08-29 Casein derived peptides and uses thereof in therapy PL375113A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/942,121 US20020147144A1 (en) 2000-03-01 2001-08-30 Casein derived peptides and uses thereof in therapy

Publications (1)

Publication Number Publication Date
PL375113A1 true PL375113A1 (en) 2005-11-28

Family

ID=25477603

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02375113A PL375113A1 (en) 2001-08-30 2002-08-29 Casein derived peptides and uses thereof in therapy

Country Status (15)

Country Link
EP (1) EP1556074A4 (en)
JP (1) JP2005511499A (en)
KR (1) KR20040078639A (en)
CN (1) CN1694719A (en)
AU (1) AU2002324323A2 (en)
BR (1) BR0212625A (en)
CA (1) CA2458924A1 (en)
CZ (1) CZ2004335A3 (en)
HU (1) HUP0500995A3 (en)
IL (1) IL160548A0 (en)
MX (1) MXPA04001890A (en)
NO (1) NO20040880L (en)
PL (1) PL375113A1 (en)
WO (1) WO2003018606A2 (en)
ZA (1) ZA200401574B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0313892D0 (en) * 2003-06-16 2003-07-23 Hannah Res Inst Control of lactation
AU2005209845A1 (en) * 2004-01-30 2005-08-18 Chemgenex Pharmaceuticals, Inc. Naphthalimide dosing by N-acetyl transferase genotyping
EP1751179A4 (en) * 2004-03-01 2009-03-25 Peptera Pharmaceuticals Ltd Casein derived peptides and therapeutic uses thereof
GB0423352D0 (en) * 2004-10-21 2004-11-24 Hannah Res Inst "Control of mammary cell number"
ES2319475B1 (en) * 2005-06-08 2010-02-16 Consejo Superior Investig. Cientificas BIOACTIVE PEPTIDES IDENTIFIED IN ENZYMATIC HYDROLYZES OF LACTEE CASEINS AND PROCEDURE OF OBTAINING.
CN101410131B (en) 2006-06-09 2012-09-12 森永乳业株式会社 Lipid-metabolism-improving agent
JP2011026213A (en) * 2009-07-22 2011-02-10 Snow Brand Milk Prod Co Ltd Type 1 diabetes-inhibiting peptide
JP2015520129A (en) * 2012-04-16 2015-07-16 ザ クリーブランド クリニック ファウンデーション Multivalent breast cancer vaccine
US20190381128A1 (en) * 2017-03-03 2019-12-19 Morinaga Milk Industry Co., Ltd. GLP-1 Secretagogue and Composition
CN107814835B (en) * 2017-12-01 2020-04-28 熊猫乳品集团股份有限公司 Bioactive polypeptide AVPITPTLNREQ, and preparation method and application thereof
CN108017709B (en) * 2017-12-12 2020-04-10 浙江辉肽生命健康科技有限公司 Bioactive polypeptide KEPMIGVNQELA, and preparation method and application thereof
CN113952446B (en) * 2021-09-03 2023-12-05 河南省医药科学研究院 Application of bioactive peptide in inhibiting bone marrow toxicity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3778426A (en) * 1970-12-16 1973-12-11 Research Corp Therapeutically useful polypeptides
JP4191261B2 (en) * 1997-03-21 2008-12-03 雪印乳業株式会社 Iron casein complex and its production method
IL134830A0 (en) * 2000-03-01 2001-05-20 Chay 13 Medical Res Group N V Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them

Also Published As

Publication number Publication date
CZ2004335A3 (en) 2004-07-14
KR20040078639A (en) 2004-09-10
EP1556074A2 (en) 2005-07-27
IL160548A0 (en) 2004-07-25
BR0212625A (en) 2007-06-19
HUP0500995A2 (en) 2007-05-02
NO20040880L (en) 2004-04-20
WO2003018606A9 (en) 2004-04-08
EP1556074A4 (en) 2008-05-07
JP2005511499A (en) 2005-04-28
CA2458924A1 (en) 2003-03-06
AU2002324323A2 (en) 2003-03-10
WO2003018606A3 (en) 2005-05-06
MXPA04001890A (en) 2004-06-18
HUP0500995A3 (en) 2008-09-29
ZA200401574B (en) 2007-02-28
WO2003018606A2 (en) 2003-03-06
CN1694719A (en) 2005-11-09

Similar Documents

Publication Publication Date Title
EP1261360A4 (en) Casein derived peptides and uses thereof in therapy
WO2005081628A3 (en) Casein derived peptides and therapeutic uses thereof
ATE314095T1 (en) VIRUS-LIKE PARTICLES FOR INDUCING AUTOANTIBODIES
AU3698697A (en) Method for preserving infectious recombinant viruses, aqueous viral suspension and use as medicament
DE69838986D1 (en) POLYPEPTIDES, THEIR PREPARATION AND USE
ATE486614T1 (en) COMPOSITIONS FOR USE IN GENE THERAPY FOR THE TREATMENT OF HEMOPHILIA
KR20040078639A (en) Casein derived peptides and uses thereof in therapy
GB2367061A (en) Peptides
FR2870126A1 (en) RECOMBINANT LENTIVIRAL VECTOR FOR EXPRESSION OF FLAVIVIRIDAE PROTEIN AND ITS APPLICATIONS AS VACCINE
DK0783585T3 (en) Defective recombinant adenoviruses with an inactivated IVa2 gene
AU5489500A (en) Isolation of a human retrovirus
WO2004006843A3 (en) Combination therapies with l-fmau for the treatment of hepatitis b virus infection
MD2053B1 (en) Remedy with interferon inducing action
GB0415437D0 (en) Recombinant virus
MXPA05007901A (en) Hcv combination therapy.
DK1250422T3 (en) Myeloid colony-stimulating factor and uses thereof
NO964894D0 (en) Recombinant viruses, their preparation and use of gene therapy
WO2001087333A3 (en) Immune system stimulating means

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)